Agios Pharmaceuticals (AGIO) Stock Price, Quote, News & History | Benzinga

SPY767.66−0.25%QQQ721.20−1.06%BTC/USD80,974.23−0.73%DIA517.39+0.34%GLD380.35+1.16%TLT80.11+1.55%

Agios Pharmaceuticals Inc (AGIO) Stock Price, Quote, News & History

AGIONASDAQ

Trade with Public

Trade with Public

$30.97

0.762.52%

Last update: Oct 15, 7:39 AM

$31.25

1.043.44%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$30.97

Volume / Avg.

2.58K / 1.07M

Day Range

$31.25 - $31.25

52 Wk Range

22.24 - 46.00

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

36

Short Interest

11.87%

Days to Cover

6.44

Recent Agios Pharmaceuticals, Inc. News

Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.

Avi Kapoor

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development

Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.

Vandana Singh

Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.

Avi Kapoor

Why Is Agios Pharma Stock Soaring Tuesday?

Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.

Vandana Singh

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday

US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-360.60M

Investing Cash Flow (TTM)

367.15M

Financing Cash Flow (TTM)

12.22M

Free Cash Flow (TTM)

-390.25M

Capital Expenditure (TTM)

-29.66M

Net Change in Cash (TTM)

18.78M

Analyst Trends and Forecast

1

1

Jun

6

Jul

1

Aug

1

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.26B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

18.50

PB Ratio (TTM)

1.80

Earnings Yield % (TTM)

-22.62%

Earnings Yield % (FWD)

-12.62%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$17.19

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$99.65M

Debt to Equity

0.03

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-